Suite 25, 145 Stirling Highway, NEDLANDS, 6009
08 9389 3170
Medibio Limited (ASX:MEB) is an Australian listed company focused on the validation and commercialisation of its exciting new circadian heart rate variability technology acquired via the acquisition of Invatec Health. After a decade of research and development based on more than 5,000 patients, the company is now planning trials to support regulatory approval of the CRV diagnostic for depression and other mental illnesses. Medibio Limited was previously named BioProspect Limited (ASX: BPO). The company changed its name on 1 December 2014 as part of a corporate transformation, with new assets, a new Board and new management.
Bio last updated 09 Dec 2015

Article Timeline

Access to our data for Medibio is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Medibio is included in 1 list - Public Companies - Industrial.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

To access ,

Medibio (MEB)

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/03/18

1 year TSR5 year TSR
371stBauMart Holdings9%0%
490thResonance Health-7%8%
716 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$0 Bought
$19k Issued
$10k Bought
Total value as at the date of the transaction
Source: Morningstar


117th↓Resonance Health$2.5m
119th↑BauMart Holdings$2.5m
236 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from Medibio

869thRobert Lees$126k
894thFrank Prendergast$119k
573rdChris Indermaur$50k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer